2,040 Shares in Repligen Co. (NASDAQ:RGEN) Bought by Everence Capital Management Inc.

Everence Capital Management Inc. purchased a new stake in Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,040 shares of the biotechnology company’s stock, valued at approximately $294,000.

A number of other hedge funds also recently made changes to their positions in the business. Andra AP fonden bought a new stake in Repligen in the second quarter valued at about $25,000. UMB Bank n.a. boosted its holdings in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. boosted its holdings in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares in the last quarter. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the 3rd quarter valued at approximately $37,000. Finally, Quarry LP raised its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on RGEN. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Finally, StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $185.20.

Repligen Trading Down 0.4 %

Shares of RGEN opened at $153.50 on Wednesday. The stock’s fifty day simple moving average is $145.29 and its 200-day simple moving average is $142.71. The firm has a market capitalization of $8.60 billion, a PE ratio of -414.85, a price-to-earnings-growth ratio of 4.64 and a beta of 0.97. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.23 EPS. As a group, research analysts predict that Repligen Co. will post 1.54 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.